General information about U.S. regulatory definitions — not legal, medical, or manufacturing advice.

Sourcing a peptide new chemical entity (NCE) is not the same problem as sourcing a peptide API that's already a component of an approved drug. An NCE is, by definition, something FDA has never approved before — which changes which compounding pathways are closed, which GMP citation actually applies, and how much CMC documentation an IND-stage buyer should expect at the door. Generic peptide-supplier pages don't carry this distinction; here is the primary-sourced version.

What makes a peptide a "new chemical entity" under FDA rules?

A new chemical entity is defined by absence, not by any property of the molecule itself: it is a drug containing no active moiety that FDA has previously approved in any new drug application filed under FD&C Act §505(b), per 21 CFR § 314.108(a). That single fact — nothing like this active moiety has an approved NDA anywhere — is what drives every downstream sourcing question below. It also means an NCE arrives with no inherited regulatory shortcut: unlike a peptide API that already sits inside an approved product, a true NCE has to earn its documentation and its pathway from scratch.

What GMP standard should an NCE manufacturing partner meet?

Not 21 CFR Part 211 — ask for cGMP under FD&C Act §501(a)(2)(B), elaborated by FDA's API guidance. Under 21 U.S.C. § 351(a)(2)(B), a drug is deemed adulterated if the methods, facilities, or controls used in its manufacture, processing, packing, or holding don't conform to current good manufacturing practice — this is the statutory cGMP hook for drug-substance and API manufacturing. Part 211 covers finished pharmaceuticals, not the drug substance stage an NCE occupies, so a supplier quoting Part 211 alone is citing the wrong chapter.

FDA's operative elaborating document is "Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients," issued jointly by CDER and CBER under ICH and supplemented by an April 2018 Q&A — current, final guidance, not withdrawn (FDA Q7A guidance). It applies even though an NCE isn't itself a finished, approved drug, because the FD&C Act's definition of "drug" extends to "articles intended for use as a component" of a drug under 21 U.S.C. § 321(g)(1)(D) — which is why cGMP and adulteration provisions reach an API/NCE at all. Cornerstone Peptide's own capabilities and quality pages describe how that standard shows up in practice, from specification-setting through release testing.

Can an NCE supplier compound with my peptide API under §503A?

No, not under ordinary circumstances. FD&C Act §503A(b)(1)(A)(i) permits 503A compounding with a bulk drug substance only if it complies with an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on an FDA-developed list of permitted substances when neither of the first two applies, per 21 U.S.C. § 353a(b)(1)(A)(i). Because an NCE by definition contains no active moiety in any FDA-approved NDA, it cannot satisfy the "component of an FDA-approved drug" pathway — so compounding using a true NCE would require USP/NF monograph status (essentially never true for a novel research entity) or placement on FDA's 503A bulk-substances list.

That list and its current conditions are addressed in FDA's final "Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A," issued January 2025, which finalized a December 2023 draft and replaced the 2017 version (FDA interim policy guidance). For the broader drug-vs-biologic and compounding framework an NCE sits inside, see our guide to how U.S. law classifies and regulates peptides.

How much CMC documentation does an IND-stage buyer need from an NCE supplier?

Enough to match your phase of investigation — not a fixed package. 21 CFR § 312.23(a)(7) requires an IND's Chemistry, Manufacturing, and Controls section to cover composition, manufacture, and control of both the drug substance and drug product, with the amount of information required scaling by phase, formulation type, and study duration. For an initial Phase 1 submission, FDA's current guidance on Phase 1 IND content puts the emphasis on identification and control of raw materials and the new drug substance itself, with acceptable limits and analytical methods assuring identity, strength, quality, and purity, plus stability data sufficient to support the planned studies (FDA, Content and Format of INDs for Phase 1 Studies, November 1995). An NCE supplier should be able to produce that identity/purity/stability package before you file, not after FDA asks a question about it.

What does "FDA-inspected manufacturing partner" actually mean for an NCE supplier?

It describes the facility's inspection and cGMP status as an API manufacturer under §501(a)(2)(B) and Q7A — it is not a claim that the NCE itself, or any commercial supply partner, holds FDA approval or registration for that compound. No NCE can hold an approval; by the 21 CFR § 314.108(a) definition, nothing like it has one yet. Specific registrations, inspection history, and current certificates for a manufacturing partner are the kind of detail that's released to qualified buyers under NDA rather than published — that's what our buyer portal exists to gate.

Sourcing NCEs for development and IND work

Development and IND buyers evaluating a new chemical entity should ask for the same three things regardless of supplier: the 21 CFR § 314.108(a) basis for calling it an NCE, the 21 U.S.C. § 351(a)(2)(B) / Q7A manufacturing standard behind the lot, and a CMC package sized to your phase under 21 CFR § 312.23(a)(7). Browse the Cornerstone Peptide catalog for current NCE and custom-synthesis listings, each with the identity and analytical documentation to evaluate against that standard.

Frequently asked questions

Can an NCE supplier compound with my peptide API under §503A? Not under ordinary circumstances — an NCE fails the "component of an FDA-approved drug" pathway in 21 U.S.C. § 353a(b)(1)(A)(i), leaving only USP/NF monograph status or FDA 503A-list placement, neither of which ordinarily applies to a novel entity.

What GMP standard should an NCE manufacturing partner meet? 21 U.S.C. § 351(a)(2)(B) cGMP as elaborated by FDA's Q7A guidance for active pharmaceutical ingredients — not 21 CFR Part 211.

How much CMC documentation does an IND-stage buyer need? 21 CFR § 312.23(a)(7) scales the requirement by phase; for an initial Phase 1 IND, identity, strength, quality, purity, and supporting stability data, per FDA's 1995 Phase 1 IND guidance.

What does "FDA-inspected manufacturing partner" actually mean? The facility is subject to inspection and §501(a)(2)(B)/Q7A cGMP obligations as an API manufacturer — it does not mean the NCE, defined under 21 CFR § 314.108(a), or the supply partner itself holds any FDA approval or registration for that compound.